$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones index closed lower by around 0.2% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Aclaris Therapeutics

  • The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard bought a total of 1,611,200 shares at an average price of $1.11. To acquire these shares, it cost around $1.78 million.
  • What’s Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.
  • What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.


  • The Trade: Zomedica Corp. (NYSE:ZOM) Vice President of Sales Russell Kevin Klass acquired a total of 299,993 shares at an average price of $0.16. To acquire these shares, it cost around $46,529.
  • What’s Happening: On May 15, Zomedica announced the launch of Over-the-Air software and firmware update capability for its TRUFORMA point-of-care diagnostic platform.
  • What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.

Perspective Therapeutics

  • The Trade: Perspective Therapeutics, Inc. (NASDAQ:CATX) CEO Johan M. Spoor acquired a total of 100,000 at an average price of $1.17. The insider spent around $117,430 to buy those shares.
  • What’s Happening: On June 11, Perspective Therapeutics announced a 1-for-10 reverse stock split.
  • What Perspective Therapeutics Does: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body.

Now Read This: Top 3 Tech Stocks That May Fall Off A Cliff This Month

More Sponsored Headlines